KEGG   DRUG: Atazanavir and cobicistat
Entry
D10753            Mixture   Drug                                   
Name
Atazanavir and cobicistat;
Evotaz (TN)
  Abbr
ATV/c
Product
EVOTAZ (E.R. Squibb & Sons)
Component
(Atazanavir sulfate [DR:D01276] | Atazanavir [DR:D07471]), Cobicistat [DR:D09881]
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01641  CYP2C8 inhibitor
 DG01645  CYP2D6 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
 DG02887  UGT1A1 inhibitor
Transporter inhibitor
 DG01622  ABCB1 inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
ATC code: J05AR15
Product: D10753<US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Atazanavir is an inhibitor of CYP3A and UGT1A1 and a weak inhibitor of CYP2C8.
Cobicistat is an inhibitor of CYP3A and CYP2D6. The transporters that cobicistat inhibits include P-glycoprotein (P-gp), BCRP, OATP1B1 and OATP1B3.
Atazanavir and cobicistat are CYP3A4 substrates.
Target
HIV protease [KO:K22599]
  Pathway
ko03230  Viral genome structure
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]; CYP2C8 [HSA:1558]
Enzyme inhibition: UGT1A1 [HSA:54658]
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR15 Atazanavir and cobicistat
      D10753  Atazanavir and cobicistat <US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Atazanavir Sulfate/ Cobicistat
    D10753  Atazanavir and cobicistat
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D10753  Atazanavir and cobicistat
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D10753  Atazanavir and cobicistat
 Metabolizing enzyme inhibitor
  DG01641  CYP2C8 inhibitor
   D10753  Atazanavir and cobicistat
  DG01645  CYP2D6 inhibitor
   D10753  Atazanavir and cobicistat
  DG02852  CYP3A/CYP3A4 inhibitor
   D10753  Atazanavir and cobicistat
  DG02887  UGT1A1 inhibitor
   D10753  Atazanavir and cobicistat
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10753  Atazanavir and cobicistat
  DG02862  ABCG2 inhibitor
   D10753  Atazanavir and cobicistat
  DG02865  SLCO1B1 inhibitor
   D10753  Atazanavir and cobicistat
  DG02907  SLCO1B3 inhibitor
   D10753  Atazanavir and cobicistat
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D10753  Atazanavir and cobicistat
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HIV protease inhibitor
    D10753  Atazanavir and cobicistat <US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10753
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10753
 Drug transporters
  D10753
Other DBs
PubChem: 273220349
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system